Id: acc2539
Group: 2sens
Protein: THOC5
Gene Symbol: THOC5
Protein Id: Q13769
Protein Name: THOC5_HUMAN
PTM: phosphorylation
Site: Tyr225
Site Sequence: LKEIEVKKEYLSSLQPRLNSI
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: CML
Disease Cellline: K562
Disease Info:
Drug: dasatinib
Drug Info: "Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL and SRC family kinases, used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in patients resistant or intolerant to prior therapy including imatinib."
Effect: sensitize
Effect Info: "The phosphorylation level of THOC5 increases in myeloid leukemia, and this phosphorylation is highly sensitive to drugs used for treating chronic myeloid leukemia (CML)."
Note:
Score: 5.0
Pubmed(PMID): 23032722
Sentence Index:
Sentence:

Sequence & Structure:

MSSESSKKRKPKVIRSDGAPAEGKRNRSDTEQEGKYYSEEAEVDLRDPGRDYELYKYTCQELQRLMAEIQDLKSRGGKDVAIEIEERRIQSCVHFMTLKKLNRLAHIRLKKGRDQTHEAKQKVDAYHLQLQNLLYEVMHLQKEITKCLEFKSKHEEIDLVSLEEFYKEAPPDISKAEVTMGDPHQQTLARLDWELEQRKRLAEKYRECLSNKEKILKEIEVKKEYLSSLQPRLNSIMQASLPVQEYLFMPFDQAHKQYETARHLPPPLYVLFVQATAYGQACDKTLSVAIEGSVDEAKALFKPPEDSQDDESDSDAEEEQTTKRRRPTLGVQLDDKRKEMLKRHPLSVMLDLKCKDDSVLHLTFYYLMNLNIMTVKAKVTTAMELITPISAGDLLSPDSVLSCLYPGDHGKKTPNPANQYQFDKVGILTLSDYVLELGHPYLWVQKLGGLHFPKEQPQQTVIADHSLSASHMETTMKLLKTRVQSRLALHKQFASLEHGIVPVTSDCQYLFPAKVVSRLVKWVTVAHEDYMELHFTKDIVDAGLAGDTNLYYMALIERGTAKLQAAVVLNPGYSSIPPVFQLCLNWKGEKTNSNDDNIRAMEGEVNVCYKELCGPWPSHQLLTNQLQRLCVLLDVYLETESHDDSVEGPKEFPQEKMCLRLFRGPSRMKPFKYNHPQGFFSHR

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

THOC5-Ser16
Cancer Intensity
BRCA 0.302
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.452
LUSC
non_ccRCC
PDAC -1.085
UCEC 1.235
THOC5-Ser28
Cancer Intensity
BRCA -1.591
COAD -1.372
HGSC -0.358
ccRCC
GBM 0
HNSC 0.966
LUAD 0.251
LUSC -0.241
non_ccRCC 1.804
PDAC 0.257
UCEC 0.284
THOC5-Ser307
Cancer Intensity
BRCA 1.147
COAD -0.044
HGSC
ccRCC 0.746
GBM -1.828
HNSC -1.118
LUAD 0.072
LUSC 0.235
non_ccRCC -0.966
PDAC 0.894
UCEC 0.861
THOC5-Ser312
Cancer Intensity
BRCA -0.674
COAD -0.778
HGSC
ccRCC 0.683
GBM -1.125
HNSC -0.544
LUAD -0.722
LUSC -0.344
non_ccRCC 2.009
PDAC 0.507
UCEC 0.989
THOC5-Ser314
Cancer Intensity
BRCA -0.767
COAD -0.981
HGSC
ccRCC 0.646
GBM -1.225
HNSC 0.057
LUAD -0.64
LUSC -0.431
non_ccRCC 1.963
PDAC 0.435
UCEC 0.943
THOC5-Thr328
Cancer Intensity
BRCA 0.593
COAD -0.13
HGSC 2.591
ccRCC -0.302
GBM -0.255
HNSC -0.06
LUAD -0.005
LUSC 0.156
non_ccRCC -1.423
PDAC -0.464
UCEC -0.701

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 225 U Chronic myelogenous leukemia/chronic myeloid leukemia Phosphorylation 23032722

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: